Quantcast

Latest Drug-eluting stent Stories

2014-09-18 12:30:22

DUBLIN, Sept. 18, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "China PTCA Balloon Market Investment Report, 2014-2016" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations. Therefore, the development of PTCA balloon industry is closely related...

2014-09-18 04:21:14

WASHINGTON, September 18, 2014 /PRNewswire/ -- The world's first and only dual therapy stent Prof. Stephen W.L. Lee presented two-year optical coherence tomography (OCT) findings and three-year clinical follow up from the EGO COMBO study, providing further evidence to support the healing benefits of the COMBO Dual Therapy Stent, the only drug eluting stent (DES) with active EPC capture technology. The findings were presented during the 26th...

2014-09-16 08:29:53

-- Differentiated Design Yields Excellent Tissue Healing and Sustained Safety Profile -- DURHAM, N.C., Sept. 16, 2014 /PRNewswire/ -- Micell Technologies, Inc. today announced that three-year clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES(®)) were presented at the 26th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference being held in Washington, D.C., September 13-17....

2014-09-15 23:08:28

ChinaMarketResearchReports.com adds Latest Report on “China PTCA Balloon Market Investment Report, 2014-2016” to its store. Inquire before buying on this report at http://www.chinamarketresearchreports.com/contacts/inquire-before-buy.php?name=114907 Dallas, TX (PRWEB) September 15, 2014 PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations....

2014-09-15 12:26:57

- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device used in the heart that functions like a stent but dissolves over time ABBOTT PARK, Ill., Sept. 15, 2014 /PRNewswire/ -- Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. Absorb is the...

2014-09-14 12:20:52

- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device, used in the heart, that functions like a stent but dissolves over time WASHINGTON, Sept. 14, 2014 /PRNewswire/ -- Abbott announced today positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic XIENCE family of DES. The trial,...

2014-08-06 08:32:12

SINGAPORE, Aug. 6, 2014 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its first fiscal quarter ended 30 June 2014 ("Q1 FY15"). Quarter Highlights and Recent Developments: -- Total revenue was US$80.2 million, representing a 5% growth from the quarter ended 30 June 2013 ("Q1 FY14")....

2014-08-04 12:26:09

LONDON, Aug. 4, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Peripheral Vascular Devices - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2012-2018 http://www.reportbuyer.com/pharma_healthcare/medical_devices/peripheral_vascular_devices_emerging_markets_brazil_russia_india_china_south_africa_south_korea_2009_2015.html Global Market Watch: BRICSS Peripheral Vascular Devices sector forecasts to reach at US$732 million by 2016....

2014-07-22 12:28:16

Although Procedure Volume Expansion Is Faster Than Other Developed Markets, This Will Be Largely Offset By Price Declines, According to Findings from Decision Resources Group BURLINGTON, Mass., July 22, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for interventional cardiology (IC) devices in Canada will remain relatively stagnant at a value of around $80 million through 2022. This is despite the fact that percutaneous coronary intervention (PCI) volumes are growing...

2014-07-21 16:26:15

Advanced Bare-Metal Stent Provides Additional Treatment Option for Interventional Cardiologists and Patients MARLBOROUGH, Mass., July 21, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the REBEL(TM) Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of coronary artery disease (CAD). Bare-metal stents continue to play an important role in the treatment of CAD and represent a...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'